The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 06, 2007
Filed:
Apr. 06, 2004
James a Hendrix, Hillsborough, NJ (US);
Horst Hemmerle, Bad Soden, DE;
Matthias Urmann, Eschborn, DE (US);
Gregory M Shutske, Pittstown, NJ (US);
Jospeh T Strupczewski, Flemington, NJ (US);
Kenneth J Bordeau, Kintnersville, PA (US);
John G Jurcak, Bethlehem, PA (US);
Thaddeus Nieduzak, Bridgewater, NJ (US);
Sharon a Jackson, Whitehouse Station, NJ (US);
Paul Angell, Liberty Township, OH (US);
James P Carey, Cincinnati, OH (US);
George Lee, Somerville, NJ (US);
David Fink, Lebanon, NJ (US);
Jean-fancois Sabuco, Paris, FR;
Yulin Chiang, Convent Station, NJ (US);
Nicola Collar, Madison, NJ (US);
James A Hendrix, Hillsborough, NJ (US);
Horst Hemmerle, Bad Soden, DE;
Matthias Urmann, Eschborn, DE (US);
Gregory M Shutske, Pittstown, NJ (US);
Jospeh T Strupczewski, Flemington, NJ (US);
Kenneth J Bordeau, Kintnersville, PA (US);
John G Jurcak, Bethlehem, PA (US);
Thaddeus Nieduzak, Bridgewater, NJ (US);
Sharon A Jackson, Whitehouse Station, NJ (US);
Paul Angell, Liberty Township, OH (US);
James P Carey, Cincinnati, OH (US);
George Lee, Somerville, NJ (US);
David Fink, Lebanon, NJ (US);
Jean-Fancois Sabuco, Paris, FR;
Yulin Chiang, Convent Station, NJ (US);
Nicola Collar, Madison, NJ (US);
Aventis Pharmaceuticals Inc., Bridgewater, NJ (US);
Abstract
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.